Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

This ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the Omicron BA.4/BA.5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan-Hu-1 mRNA-1273 as booster doses. Two groups of adults who previously received mRNA-1273 as primary vaccination series and boost...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalkias, Spyros, Whatley, Jordan L., Eder, Frank, Essink, Brandon, Khetan, Shishir, Bradley, Paul, Brosz, Adam, McGhee, Nichole, Tomassini, Joanne E., Chen, Xing, Zhao, Xiaoping, Sutherland, Andrea, Shen, Xiaoying, Girard, Bethany, Edwards, Darin K., Feng, Jing, Zhou, Honghong, Walsh, Stephen, Montefiori, David C., Baden, Lindsey R., Miller, Jacqueline M., Das, Rituparna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504066/
https://www.ncbi.nlm.nih.gov/pubmed/37653342
http://dx.doi.org/10.1038/s41591-023-02517-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504066/
https://www.ncbi.nlm.nih.gov/pubmed/37653342
http://dx.doi.org/10.1038/s41591-023-02517-y

Ejemplares similares